GlassScriptPhysician profile
Veryl Hodges
NPI 1013903269
$8,149.26
in general payments reported to CMS, 2019-2025
45 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,224 · 2020: $1,660 · 2021: $2,125 · 2022: $142 · 2023: $380 · 2024: $266 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $779.64 | 2019-2025 | Breztri |
| Pfizer INC. | $769.26 | 2019-2025 | |
| Abbvie INC. | $754.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $679.65 | 2019-2021 | |
| Astellas Pharma US INC | $512.14 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $476.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $439.98 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $364.09 | 2019-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $356.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $344.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.77 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $227.98 | 2019-2025 | Gardasil 9, Capvaxive |
| Lilly USA, LLC | $206.70 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $192.79 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $176.00 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veryl Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.